Alan Ezekowitz Acquires Organon & Co. Shares
Alan Ezekowitz purchased 17,857 shares of Organon & Co. for approximately $239,998.
Key Points
- Alan Ezekowitz bought 17,857 shares of Organon & Co. at $13.44 per share on June 12, 2026.
- Organon & Co. shares trade near $13.44 with a market cap of about $3.53 billion.
- Recent analyst actions include BNP Paribas downgrading the stock to hold with a $14 target.
On June 12, 2026, Alan Ezekowitz purchased 17,857 shares of Organon & Co. (NYSE: OGN) at a price of $13.44 per share. This transaction was valued at approximately $239,998 and was not part of a pre-planned trading program.
Insider Buying and Selling at Organon & Co.
Alongside Alan Ezekowitz, several other insiders bought shares of Organon & Co. on June 12, 2026. Each insider, including Shalini Sharp, Philip Ozuah, Ramona Sequeira, Deborah Leone, and Robert Essner, acquired 17,857 shares at the same price of $13.44 per share.
Other Institutional Activity in Organon & Co.
In recent institutional activity, BlackRock, Inc. increased its holdings in Organon & Co. by 751,009 shares, ending with 31,717,028 shares valued at about $189.98 million. Vanguard Portfolio Management LLC took a new position with 21,846,036 shares worth approximately $130.86 million. Meanwhile, State Street Corp added 359,013 shares to hold a total of 9,956,774 shares, valued at $59.64 million. On the other hand, LSV Asset Management reduced its stake by 212,699 shares, leaving it with 7,259,730 shares valued at $43.49 million.
Organon & Co. Stock Snapshot
Shares of NYSE:OGN traded near $13.44. Organon & Co. has a market cap of approximately $3.53 billion and a P/E ratio of 14.45. The stock's 52-week range is between $5.69 and $13.49, with a 50-day moving average of $11.88 and a 200-day moving average of $9.04. The company has a current ratio of 1.97 and a debt-to-equity ratio of 948.95.
Recent Earnings
Organon & Co. reported revenue of $6.16 billion with a revenue decline of 3.5%. The company's earnings per share stood at $0.93, with a net margin of 3.99% and a return on equity of 34.05%. The next earnings report is expected on August 4, 2026.
Dividend
Organon & Co. offers an annual dividend rate of $0.08, yielding 0.6% with a payout ratio of 8.6%.
Analysts Set New Price Targets
On April 29, 2026, BNP Paribas downgraded Organon & Co. to a hold rating with a price target of $14. Piper Sandler upgraded the stock to hold with the same target on April 28, 2026. The consensus among analysts is a hold rating, with an average target price of $11.25 based on four analyst opinions.
About Organon & Co.
Organon & Co., headquartered in Jersey City, New Jersey, is a healthcare company specializing in women's health solutions. It offers a range of prescription therapies and medical devices globally, including contraceptives and fertility treatments. The company also has a portfolio of biosimilars and products for cholesterol management, hypertension, and respiratory conditions. Led by CEO Joseph T. Morrissey Jr., Organon & Co. employs around 10,000 people.
Bottom Line
Alan Ezekowitz's recent purchase of Organon & Co. shares highlights insider interest in the company. With a market cap of $3.53 billion and a diverse healthcare portfolio, Organon & Co. is a key player in the sector. Investors often track insider transactions like these for insights, though such filings are retrospective and may not reflect current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.